Shots: Fresenius Kabi and Medec collaborated to offer IDACIO as an additional therapy option for rheumatologists and dermatologists to treat rheumatic illnesses. From Jun 01, 2020, Medec’s will market the […]readmore
Tags : Idacio
Shots: The launch of Idacio is based on its MAA approval by EC for all indications of the reference product in therapy areas of rheumatology, dermatology and gastroenterology The approval […]readmore
Biosimilars
Biotech
Fresenius Kabi’s Idacio (adalimumab, biosimilar) Receives EU’s Marketing Approval in
Shots: The approval is based on its non-inferiority data consisting of its PK, efficacy, safety, immunogenicity data with the reference product in analytical, preclinical and clinical data trials Fresenius Kabi […]readmore